Plandai Biotechnology Inc (OTCMKTS:PLPL) Files Form 10-Q

Plandai Biotechnology Inc (OTCMKTS:PLPL) reported that for the quarter ending March 31, 2015, the revenue came at $21,744 against revenues of $12,554 for the three months period completed March 31, 2014. The sales comprises of timber sales from the company’s tea estate business in South Africa.

The cost of sales for the quarter completed March 31, 2015 stood at $181,214 versus $141,046 in the same period, a year earlier. It marked an increase of $40,168 YOY. This increase in cost of sales can be attributed to expenses incurred in operating the factory in 2015 and other expenses related with operating activities of the Senteeko Tea Estate.

Ritter Pharmaceuticals Inc (NASDAQ:RTTR) Gains In Early Morning Trade

In early morning trade on Thursday, the stock price of Ritter Pharmaceuticals Inc (NASDAQ:RTTR) gained more than 4% and is trading close to $3.39. The pharmaceutical firm advancing innovative therapeutic products recently revealed that the company has retained Mr. William (Bill) Merino as Senior clinical and regulatory advisor.

Dr. Merino has extensive experience working with the international and U.S. pharmaceutical firms and assisting them in various operations including approval process, quality control and assurance. He has served in senior regulatory affairs role at reputed companies like Alcon Pharmaceuticals and Riker Laboratories. In his new role, he will help the company in advancing the trial of lead candidate, RP-G28.

Carbylan Therapeutics Inc (NASDAQ:CBYL) Posts Quarterly Numbers

Carbylan Therapeutics Inc (NASDAQ:CBYL) announced the financial results for three-month period ending June 30, 2015. The company recorded a net loss of $9.0 million against $2.6 million in 2Q2014. David Renzi, the President and CEO stated that during the second quarter of this fiscal, they continued to focus on the advancement of Phase III clinical trial for lead drug Hydros-TA for treatment of osteoarthritis pain of the knee. Also, the company closed the enrollment in COR1.1 trial.

About the Author

John is a special projects and general assignment reporter, noted for breaking several exclusive stories.

Leave A Response